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Abstract
Lysyl oxidase (LOX), an extracellular matrix remodeling enzyme, appears to have a role in promoting breast cancer cell
motility and invasiveness. In addition, increased LOX expression has been correlated with decreases in both metastases-free,
and overall survival in breast cancer patients. With this background, we studied the ability of b-aminopropionitrile (BAPN),
an irreversible inhibitor of LOX, to regulate the metastatic colonization potential of the human breast cancer cell line, MDA-
MB-231. BAPN was administered daily to mice starting either 1 day prior, on the same day as, or 7 days after intracardiac
injection of luciferase expressing MDA-MB-231-Luc2 cells. Development of metastases was monitored by in vivo
bioluminescence imaging, and tumor-induced osteolysis was assessed by micro-computed tomography (mCT). We found
that BAPN administration was able to reduce the frequency of metastases. Thus, when BAPN treatment was initiated the day
before, or on the same day as the intra-cardiac injection of tumor cells, the number of metastases was decreased by 44%,
and 27%, and whole-body photon emission rates (reflective of total tumor burden) were diminished by 78%, and 45%,
respectively. In contrast, BAPN had no effect on the growth of established metastases. Our findings suggest that LOX
activity is required during extravasation and/or initial tissue colonization by circulating MDA-MB-231 cells, lending support
to the idea that LOX inhibition might be useful in metastasis prevention.
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Introduction
Despite advances in early detection and improvements in the
treatment of breast cancer, mortality remains relatively high and is
invariably associated with the development of metastases. Indeed,
approximately one third of patients that are treated for localized
breast cancer will eventually develop recurrence at distant sites [1].
Once metastases are present, average survival decreases to
approximately 24 months [1,2]. The metastatic process is thought
to involve multiple steps, including loss of cell-to-cell and cell-to-
basement membrane adhesion, epithelial-mesenchymal transition,
and increased cell motility. After migrating though the connective
tissue and the lymphatic or vascular endothelium, cells must be
able to avoid anoikis, adhere to the microcapillary endothelium,
and then extravasate before being able to generate metastatic
colonies within favorable microenvironmental niches [3,4,5,6].
Many of these steps involve dynamic interactions between tumor
cells, stromal cells, and the extracellular matrix (ECM) [7]. In
keeping with the latter, expression microarray data has revealed
that genes encoding ECM remodeling proteins are frequently
over-expressed within the tumor stroma, and that dysregulation of
ECM-relevant genes is predictive of metastasis in both mouse and
human mammary cancers [8,9]. Within this context, lysyl oxidase
(LOX) is thought to play an important role in modulating tumor
behavior.
LOX, an extracellular matrix-remodeling enzyme, is required
for the oxidative deamination of lysine residues in collagen and
elastin molecules that is required for fiber cross-linking; hence,
LOX controls both the structure and the tensile strength of ECM,
and thus acts to preserve tissue integrity [10]. The activities of
LOX and other members of LOX family (that include both
extracellular and intracellular isoforms) are complex, having been
shown to regulate events such as chromatin compaction [11], gene
transcription [12,13], as well as cell differentiation and tissue
development [14]. The findings that LOX activity is modulated by
oxygen levels [15,16,17], and also that LOX is able to regulate cell
migration and adhesion [18,19], have generated considerable
interest in the role of LOX during tumor progression. In
particular, it has been shown that hydrogen peroxide, released
as a consequence of LOX mediated catalysis, triggers the
phosphorylation and activation of two key signal transduction
pathway activators: Src and focal adhesion kinase (FAK). FAK, for
example, activates multiple intracellular signal transduction
pathways that modulate actin filament formation, turnover of
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expression of matrix metalloproteinases; all processes that are
involved in tumor cell invasiveness and migration [17,18,19,20].
Both up- and down-regulation of LOX has been observed in
different cancer cell lines and primary tumors (reviewed in [21]),
however, in breast cancer, elevated LOX expression has been
positively-correlated with invasiveness, as well as with reduced
metastasis-free and overall survival [16,22,23,24,25]. In an elegant
series of experiments, Erler and colleagues identified a role for
LOX in breast cancer cells, showing that by reducing the activity
of this molecule (by either chemical inhibition or RNAi) lung
metastases could be greatly decreased, and liver metastases
eliminated in mice bearing orthotopic MDA-MB-231 tumors
[16]. However, the question remained as to whether LOX
inhibition was acting (a) to prevent the migration of cells away
from the primary tumor, (b) by limiting tumor cell intravasation,
(c) by blocking extravasation, or (d) by decreasing the ability of the
tumor cells to colonize favorable niches within distant sites. We
therefore evaluated the ability of the irreversible LOX inhibitor, b-
aminopropionitrile (BAPN), to regulate metastatic colonization
and growth of the MDA-MB-231 breast cancer cells following
their introduction into the arterial circulation of immunodeficient
mice. Our findings demonstrate that BAPN significantly reduced
the frequency of metastases in both soft tissue and skeletal sites,
while having no effect on the growth of established metastases.
Our findings suggest that LOX likely plays an important role in
regulating extravasation and/or tissue colonization by circulating
breast cancer cells.
Materials and Methods
Cell culture
The human breast cancer cell line, MDA-MB-231, was kindly
provided by Dr. T. Guise (University of Virginia, Charlottesville),
and were confirmed to be free of pathogenic murine viruses and
Mycoplasma spp. by PCR testing at Charles River Laboratories
(Wilmington, MA). Cells were grown in Dulbecco’s modified
Eagle medium (DMEM; Invitrogen, Grand Island, NY) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS),
100 U/ml penicillin, 100 mg/ml streptomycin at 37uCi na5 %
CO2 humidified atmosphere, and were routinely passaged every
2–3 d.
Construction of dual-reporter plasmid vector
A 1652-bp fragment of the plasmid pGL4.13 (Promega,
Madison, WI), encoding the firefly luciferase (luc2) cDNA (nt
499–2151; GenBank accession number AY738225), was PCR-
amplified using Vent DNA-polymerase (New England Biolabs,
Mississauga, ON). The primers used for the PCR-amplification
contained an EcoR1 and BamH1 site, respectively, and were: sense,
59 – ATAGAATTCATGGAAGATGCCAAAAACATTAAG;
and antisense, 59 – TATGGATCCTAGAATTATTACACGGC-
GATCTTG. The fragment encoding luciferase was then sub-
cloned into the EcoR1 and BamH1 sites within the polylinker
region of the enhanced green fluorescence protein (EGFP)-
expressing pEGFP-C2 vector (Clontech, Mountain View, CA),
such that the luciferase sequence was inserted in-frame and
downstream of the EGFP coding region. The sequence of pEGFP-
Luc2 vector was then confirmed both by restriction mapping and
DNA sequencing of the plasmid.
Transfection of breast cancer cells
MDA-MB-231 cells were stably transfected with the pEGFP-
Luc2 vector using the Lipofectamine reagent (Invitrogen)
according to the manufacturer’s instructions. Transfectants were
selected in media containing 1.2 mg/ml geneticin (Invitrogen) for
21 d, and then re-selected by fluorescence-activated cell sorting
(FACS)(Flow Cytometry Core Facility, University of Calgary) to
enrich for a population of cells that exhibited the highest EGFP
fluorescence signal intensities. Individual clones of sorted cells were
also analyzed for the expression of luciferase, and 60 clones
exhibiting the highest levels of EGFP-Luc2 expression were pooled
so as to maintain a level of potential variability comparable to that
of the parental cells. This pooled population was then expanded,
aliquoted, and stored in liquid N2, so that the identical cell
population could be used for all subsequent in vivo experiments.
Cell proliferation assay
Growth of MDA-MB-231-Luc2 and the parental MDA-MB-
231 cells was compared using 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT reagent; Sigma, St.
Louis, MO) according to the manufacturer’s instructions. Briefly,
cells were seeded in 96-well plates at 1610
3 cells per well in 100 ml
of culture medium and grown under normal conditions at 37uCi n
humidified atmosphere. After incubation for up to 5 d, the
medium was discarded and replaced with 90 ml of fresh medium,
followed by the addition of 10 ml of 5 mg/ml MTT reagent and
incubation for 4 hr at 37uC for cells to develop the formazan
product. Subsequently, the MTT-containing medium was aspi-
rated, and 100 ml of DMSO (Sigma) was added to lyse the cells
and to solubilize the formazan. Absorbance values of the lysates
were determined on a Multiskan Ascent microplate reader
(Thermo Labsystems, Helsinki, Finland), using a background
wavelength of 620 nm and a detection wavelength of 550 nm.
Luciferase expression by MDA-MB-231-Luc2 cells
Luciferase expression by MDA-MB-231 cells stably transfected
with the pEGFP-Luc2 plasmid was assessed using a Xenogen IVIS
Imaging System instrument (Caliper Life Sciences; Alameda, CA).
Briefly, serial dilutions of 2610
3 to 1610
4 cells per well were
plated into black, clear bottomed, 96-well plates (Costar; Acton,
MA). D-luciferin (Gold Bio Technology; St. Louis, MO) was then
added to a final concentration of 150 mg/ml in medium 10 min
before imaging. Bioluminescence readings were analyzed with
Living Image 3.0 software (Caliper Life Sciences; Alameda, CA).
Mice
Nude-beige (NIH-III) female mice (4–5 week old) were
purchased from Charles River Laboratories (St. Constant, QC).
Mice were housed under viral antibody-free conditions in the
biohazard area of the University of Calgary Animal Resources
Center in compliance with Canadian Council of Animal Care
guidelines and ethical approval from the University of Calgary
Animal Care Committee.
Experimental metastasis model and drug administration
To generate metastases, 5–6 week old female NIH-III mice
were anesthetized by intraperitoneal (i.p.) injection of ketamine
(100 mg/kg) and xylazine (6 mg/kg), and then 2610
5 MDA-MB-
231-Luc2 cells suspended in 100 ml of PBS were injected into the
left ventricle of each mouse as previously described [26].
Successful intra-cardiac injections were confirmed by immediate
whole body bioluminescence imaging (showing systemic distribu-
tion of bioluminescence signal), and mice were randomly assigned
to different experimental groups. BAPN intraperitoneal injections
(Sigma-Aldrich; St. Louis, MO), at a dose of 100 mg/kg in 100 ml
PBS, were initiated either 1 day prior, on the same day as, or 7
BAPN Prevents Metastasis
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were abbreviated as ‘BAPN d21’, ‘BAPN d0’, and ‘BAPN d7’).
BAPN injections were performed daily until the end of the
experiment. A control group of mice received daily i.p. injections
with vehicle (PBS) only. Numbers of animals included into the
analyses were n=10 for the ‘no BAPN’ and for ‘BAPN d7’ groups,
and n=5 for the ‘BAPN d21’ and for ‘BAPN d0’ groups.
Development of metastases was monitored via bi-weekly biolumi-
nescence imaging. Mice were sacrificed 21 d after the MDA-MB-
231-Luc2 cell injections, and femora/tibiae were harvested for
micro-computed tomography (mCT) and histology; in addition,
internal organs were harvested for the ex vivo evaluation of
bioluminescence so as to confirm the anatomical distribution of
soft tissue metastases.
Bioluminescence imaging
Bioluminescence imaging was performed as described previ-
ously [27,28,29]. Mice were administered D-luciferin (Gold Bio
Technology; St. Louis, MO) at a dose of 150 mg/kg in PBS by i.p.
injection, and anesthetized with 1.5–2% isofluorane for 10–
12 min prior to imaging. Animals were then placed onto the
warmed stage inside of the IVIS light-tight chamber and
anesthesia was maintained with 1.5–2% isofluorane. For the
image acquisition, the cooled charge coupled device (CCD)
camera of Xenogen IVIS Lumina system (Caliper Life Sciences)
was used; mice were imaged in both the dorsal and ventral
positions. Imaging parameters were f/stop 1, bin 4, field of view
12.5 cm, and exposure times ranged from 20 s to 2 min,
depending on the strength of the tumor-derived photon emission
rates. Results were analyzed using Living Image 3.0 software
(Caliper Life Sciences). Signal intensity was quantified as the total
photons/s within a uniform region of interest positioned over
specific tumor sites (as well as over the entire body) during the data
post-processing, with any background bioluminescence subtracted
out. For ex vivo imaging, organs of interest were dissected, placed
into 24-well tissue culture plates along with 300 mg/ml D-luciferin
in PBS, and imaged for 1–2 min using the IVIS system.
Micro-computed tomography
Bone loss resulting from osteolytic metastases was assessed by
mCT. Mice were sacrificed 21 d after intracardiac cell injection
and bones were dissected and cleaned of soft tissues before fixing
for at least 24 hrs in 10% neutral buffered formalin. For scanning,
bones were first rinsed in PBS, and then placed into an airtight
cylinder sample holder of a mCT scanner (mCT40, Scanco
Medical, Bru ¨ttisellen, Switzerland). Regions of interest were
selected following a scout view, and 400–800 serial tomographic
images with a 10 mm increment were acquired at 55 kV and
145 mA, and a 200 ms integration time. The three-dimensional
reconstructed images of the proximal tibia were analyzed (Image
Processing Language, v5.05a). The 3D images included a region
represented by 300 tomographic slices (3 mm) obtained immedi-
ately distal to the proximal tibial growth plate, and the raw images
were Gaussian filtered to reduce noise (s=0.7, support of three
voxels) and thresholded (255/1000) to extract mineralized bone
tissue. Total bone volume was used as a measure of the magnitude
of tumor-induced osteolysis.
Histology
Following ex vivo bioluminescence imaging, selected organs were
fixed in 10% neutral buffered formalin and long bones were fixed
in 4% paraformaldehyde in phosphate buffer for 1 week followed
Figure 1. In vitro evaluation of MDA-MB-231-Luc2 cells. (A) Cells were plated in a 96-well plate in quadruplicate, ranging from 10,000 to 2,000
cell/well. Wells with media only (no cells) were included as control. D-luciferin substrate was added to each well and the plate was imaged to estimate
the bioluminescence of MDA-MB-231-Luc2 cells. (B) Correlation between bioluminescence and cell number per well was plotted as mean photons/s/
well6SEM. (C) Fluorescence microscopy, showing that MDA-MB-231-Luc2 cells expressed EGFP. (D)1 610
3 MDA-MB-231 parental and MDA-MB-231-
Luc2 cells were seeded into quadruplicate wells of 96-well plates and their proliferation rates determined by MTT assay. Data was plotted as mean
relative growth6SEM.
doi:10.1371/journal.pone.0005620.g001
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4uC. Tissues were then processed, embedded in paraffin, sectioned
at 4 mm, and stained with hematoxylin and eosin.
Statistical analyses
All data were plotted as mean6SEM. Statistical analysis was
performed using ANOVA and Mann-Whitney t-test in GraphPad
Prizm 4.0 Software (GraphPad Software Inc., San Diego, CA).
Values of P,0.05 were considered statistically significant.
Results
Generation of luciferase-expressing MDA-MB-231 cells
MDA-MB-231 cells were stably transfected with a plasmid
encoding the EGFP-Luc2 fusion-protein as described in the
‘Materials and Methods’. FACS was then used to select the
population of cells showing the highest EGFP signals. The MDA-
MB-231-Luc2 line, composed of cells derived from the expansion
and pooling of sixty individual clones, exhibited a strong
correlation between cell number and bioluminescence signal
intensity (r
2=0.99) (Fig. 1A, B). The expression of luciferase, and
EGFP (Fig. 1C) in MDA-MB-231-Luc2 cells was stable after the
cells were cultured for several weeks in media lacking G418
selection (data not shown). After expansion, the pooled population
was frozen-back in multiple aliquots, so that all subsequent
xenografting experiments utilized the same pool of MDA-MB-
231-Luc2 cells. The light emission for these cells ranged from 733
to 937 photons/s per cell (Fig. 1B), a rate that was several times
higher than that of previously described MDA-MB-231-Luc cells
[27]. The proliferation of the parental MDA-MB-231 and MDA-
MB-231-Luc2 was similar (Fig. 1D), demonstrating that expres-
sion of the EGFP-Luc2 fusion-protein did not alter cell growth.
Effect of BAPN treatment on development of MDA-MB-
231-Luc2 metastasis and on whole body tumor burden
To evaluate the effect of LOX inhibition on the development of
metastases, we introduced MDA-MB-231-Luc2 cells into the
arterial circulation of NIH-III mice via intra-cardiac injection and
Figure 2. Growth of MDA-MB-231-Luc2 metastasis and the effects of BAPN treatment. Bioluminescence imaging was performed 2 times
per week starting on day 7 after intracardiac injection of tumor cells. Representative dorsal images of control and BAPN-treated mice are shown from
7 to 21 d post-injection (A). Images for days 7–10, and days 14 to 21 are shown with different sensitivity color scale bars, reflecting the rapid growth
rate of metastases. Scales are in photons/s/cm
2. Whole body luminescence, a measure of tumor burden, for the different groups is shown as a
function of time (B); note the need for a log scale owing to the rapid growth of the tumors. BAPN treatment was initiated at the indicated times and
then continued daily thereafter until day 21. (C) Whole body bioluminescence at day 7 post-cell injection was quantified as mean photons/s6SEM.
Whole body tumor bioluminescence at day 21 (D) was quantified as mean photons/s6SEM. For both (B) and (C), n=10 for each of ‘no BAPN’ and for
‘BAPN d 7’ groups, and n=5 for ‘BAPN d 21’ and for ‘BAPN d 0’ groups. Asterisks indicate statistical significance (
* P,0.05;
** P,0.01;
*** P,0.001).
doi:10.1371/journal.pone.0005620.g002
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using bioluminescence imaging. Mice were randomized into
different experimental groups and daily BAPN treatments were
initiated either the day before (d 21), the day of (3 hrs post-IC) (d
0), or 7 days (d 7) after MDA-MB-231-Luc2 intracardiac injection.
Initiation of treatment on d21 was selected to try determine
whether BAPN pretreatment might have an effect on early events,
such as tumor cell adherence to the vascular endothelium and/or
transmigration through the vessel wall; while BAPN given at the
3 hrs post-injection (d 0), a time when tumor cell transendothelial
migration was either in-progress or complete [3,30,31,32], was
used to evaluate whether BAPN treatment might have an effect on
the later stages of extravasation and/or on colonization of tumor
cells in target tissues. These two BAPN administration times
enabled us to obtain an idea as to whether BAPN might show a
differential effect on the earliest stages of tumor cell-vessel wall
interactions and extravasation versus the later stages of tissue
colonization. In addition, to determine whether BAPN had any
effect on the growth of established metastases, the chemical was
given to mice at 7 days (d 7) post-injection, a time when
bioluminescence signals from the metastases could be reliably
measured. Mice from the control group were injected with PBS
vehicle only.
Representative bioluminescence images of mice from all four
experimental groups, taken at days 7, 10, 14, 17, and 21 post-
intracardiac injection of MDA-MB-231-Luc2 cells, are displayed
in Figure 2A. Quantification of whole-animal photon emission
rates (Fig. 2B) allowed us to gauge relative tumor burden in the
mice over time, and revealed that BAPN had a negative effect on
the development of metastases, particularly when administered on
d 21, but was ineffective when started on day 7 post-injection
(Fig. 2C). Specifically, in the d 21 and d 0 groups, whole body
bioluminescence at day 7 post-IC was reduced by 72%
(P=0.0001) and 37% (P=0.0240), respectively, as compared to
the ‘no BAPN’ animals (Fig. 2C). Similarly, at day 21 post-
injection, whole body tumor burden was decreased by 78%
(P=0.0018) and 45%, respectively, in these two groups of mice, as
compared to the control group (Fig. 2D). BAPN administration
after metastases had already formed (d 7) again had no significant
effect on tumor growth (Fig. 2D).
BAPN reduces the number of MDA-MB-231-Luc2
metastases
There is evidence that only a small proportion of extravasated
cells go on to form metastases, while the bulk of the tumor cells
either remain dormant within their metastatic sites or undergo
apoptosis after a few cell divisions [3,33,34]. To gain insight into
whether BAPN treatment had an effect on the number of
metastases we examined bioluminescence line profiles obtained
from dorsal, lateral, and ventral images of mice (Fig. 3A, B). This
estimate revealed that when BAPN treatment was initiated either
on d 21 or d 0, the average number of metastatic sites per mouse
decreased by 44% (P=0.0028), and 27% (P=0.0284), respective-
ly, as compared to the ‘no BAPN’ controls (Fig. 3C). Adminis-
tration of BAPN after metastases had developed did not reveal any
significant reduction of number of metastases per mouse (Fig. 3C).
Anatomic distribution of MDA-MB-231-Luc2 metastases
in BAPN-treated mice
Since breast cancer cells exhibit tropisms for specific tissues
[4,26,35], we evaluated whether BAPN treatment might alter
Figure 3. Effect of BAPN administration on the number of metastases. Metastases were quantified by moving a line for measuring photon
emissions over the entire mouse image (A), and using this to count the number of bioluminescent peaks in the whole animal profile (B). Dorsal,
ventral, and lateral images taken at day 21 after cell injection were evaluated for mice that received BAPN starting at the indicated time points, and
continued daily thereafter until day 21, as well as for control (vehicle only) mice. Total number of metastases per mouse are shown as the mean6SEM
(C) (n=10 for each of ‘no BAPN’ and for ‘BAPN d 7’ groups, and n=5 for ‘BAPN d 21’ and for ‘BAPN d 0’ groups). Asterisks indicate statistical
significance (
* P,0.05;
** P,0.01).
doi:10.1371/journal.pone.0005620.g003
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Luc2 metastases was thus established via (i) bioluminescence
imaging of the mice, (ii) determination of isolated organ
bioluminescence ex vivo, and (iii) mCT imaging of the skeleton.
This analysis, carried out for the ‘no BAPN’ control group
demonstrated that MDA-MB-231-Luc2 cells were able to
metastasize to a variety of different soft tissue and skeletal sites
(Table 1), with bone metastases exhibiting a strong predilection
for specific skeletal sites, such as, the scapulae, distal femora/
proximal tibiae, ribs, pelvis, vertebral bodies, and mandible) (Fig. 4
and Table 1). Interestingly, the frequencies of tissue-specific
metastases in the mice were reminiscent of those observed in
individuals with metastatic breast cancer [36,37]. We found that
BAPN administration did not significantly alter the anatomical
distribution of metastases (Table 1).
BAPN pre-treatment inhibits the development of MDA-
MB-231-Luc2 bone metastases
Bone is the most common site of metastasis in human breast
cancer [37,38], and it was also the preferred site of MDA-MB-231-
Luc2 metastases, with one or both knees (distal femur and/or
proximal tibia) being involved 100% of the time (Table 1). To
monitor the development and progress of skeletal metastases at a
given site in response to BAPN, bioluminescence measurements,
and histological analysis were performed on the involved knees
(Fig. 5A,B), and photon emission rates were quantified as a
function of time (Fig. 5C). As with the whole body analysis, when
BAPN treatment was initiated early, knee metastases were
significantly reduced. Thus, in mice where BAPN treatment was
started on d 21, and on d 0, the average knee bioluminescence
(taken at day 7) was reduced by 89% (P=0.0001), and 63%
(P=0.0424), respectively, as compared to vehicle-injected mice
(Fig. 5D). At 21 d post-injection the average knee biolumines-
cence was still reduced in these groups of mice by 83%
(P=0.0271) for the ‘BAPN d 21’group, and by 52% for the
‘BAPN d 0’ group, as compared to controls (Fig. 5E). BAPN
treatment initiated after metastases had formed (at day 7 post-
injection) did not significantly reduce tumor bioluminescence.
These results suggest that BAPN pre-treatment reduced the
number of circulating tumor cells able to colonize the proximal
tibia in the early hours post-intracardiac injection. Thus, while not
eliminating knee metastases altogether, BAPN pre-treatment
significantly reduced tumor growth at this site (Fig. 5D,E)
perhaps as a consequence of decreased intramedullary coloniza-
tion by MDA-MB-231 cells.
To determine whether BAPN would show an effect on tumor-
induced osteolysis, quantitative mCT analysis was employed
(Fig. 6A). The knees of control mice injected with MDA-MB-
231-Luc2 cells lost about 15% of proximal tibial bone volume by
day 21 (P=0.0296), as compared to controls lacking tumors
(Fig. 6B). A similar degree of bone loss was seen in mice where
BAPN treatment was not started until d 7 post-injection
Table 1. Frequency of metastases at various anatomical sites following the intracardiac injection of MDA-MB-231-luc2 cells in
control, and BAPN-treated mice.
Site of metastases no BAPN, % (frequency) BAPN d 7, % (frequency) BAPN d 0, % (frequency) BAPN d 21, % (frequency)
Soft tissue sites:
Lungs 100 (10/10) 90 (9/10) 100 (4/4) 100 (5/5)
Heart 80 (8/10) 100 (10/10) 100 (4/4) 100 (5/5)
Peritoneum
* 70 (7/10) 30 (3/10) 25 (1/4) 0 (0/5)
Pancreas 40 (4/10) 40 (4/10) 25 (1/4) 0 (0/5)
cervical lymph nodes 30 (3/10) 40 (4/10) 25 (1/4) 40 (2/5)
adrenal gland 20 (4/20) 30 (6/20) 25 (2/8) 10 (1/10)
Ovaries 5 (1/20) 25 (5/20) 25 (2/8) 30 (3/10)
Liver 0 (0/10) 0 (0/10) 20 (1/4) 0 (0/5)
Stomach 0 (0/10) 10 (1/10) 0 (0/4) 0 (0/5)
Bladder 0 (0/10) 10 (1/10) 0 (0/4) 0 (0/5)
Skeletal sites:
knee (tibia and/or femur) 100 (20/20) 100 (20/20) 100 (10/10) 70 (7/10)
Ribs 100 (10/10) 90 (9/10) 100 (5/5) 80 (4/5)
Mandible 90 (9/10) 80 (8/10) 80 (4/5) 80 (4/5)
vertebrae
** 90 (9/10) 80 (8/10) 100 (5/5) 20 (1/5)
**
proximal femur 50 (10/20) 35 (7/20) 30 (3/10) 30 (3/10)
iliac crest 40 (8/20) 60 (12/20) 40 (4/10) 40 (4/10)
Scapulae 45 (9/20) 50 (10/20) 50 (5/10) 30 (3/10)
parietal bones of the skull 30 (3/10) 40 (4/10) 40 (2/5) 20 (1/5)
proximal humerus/shoulder 15 (3/10) 10 (2/20) 10 (1/10) 10 (1/10)
ankle/paw 10 (4/40) 18 (7/40) 10 (2/20) 0 (0/20)
pubic symphysis 10 (1/10) 50 (5/10) 0 (0/4) 0 (0/5)
*P,0.05.
**P,0.01.
doi:10.1371/journal.pone.0005620.t001
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osteolysis caused by established tumors. In contrast, when BAPN
was administered on d 21, tibial tumor size was smaller (as shown
by the reduced photon emission rates)(Fig. 5D, E), and hence,
bone volume was preserved and not significantly different from
that of age-matched mice lacking tumors (Fig. 6B).
Discussion
Non-invasive bioluminescence imaging of luciferase-expressing
tumor cells is an excellent method for following tumors in vivo,
providing not only an efficient way to quantify tumor growth over
time, but also a means with which to identify both the numbers
and anatomical sites of systemic metastases [39,40].
The vector encoding a EGFP-Luc2 fusion-protein enabled us to
use FACS to select for MDA-MB-231 transfectants with light
emission rates exceeding those of previously described breast
cancer cell lines. Thus, bioluminescence of our MDA-MB-231-
Luc2 cells, in the range of 730–930 photons/s/cell (Fig. 1A, B),
was higher than the 130–210 photons/s/cell obtained for
individual clones of MDA-MB-231-Luc [27], or the 37–51
photons/s/cell reported for MDA-MB-435-luc cells [40]. Lucifer-
ase expression in our model allowed us to reliably quantify tumor
burden in mice as early as 7 d after intra-cardiac injection of
MDA-MB-231-Luc2 cells.
We used the MDA-MB-231-Luc2 xenograft system to demon-
strate that the LOX inhibitor, b-aminopropionitrile, was able to
decrease tissue colonization by MDA-MB-231-Luc2 cells following
their intra-cardiac administration. Thus, BAPN pretreatment (day
21) significantly reduced not only the number of metastases that
developed but also the whole animal tumor burden. The former
result suggested that the numbers of cells ‘seeding’ a given tissue
site had been reduced by BAPN pre-treatment. When BAPN
initiated 3 hrs after tumor cell injection, there was less of an
inhibition on metastasis development, suggesting that this agent
was most effective when it was able to act on tumor cells and/or
host tissues during the initial phase of the extravasation process.
Although BAPN pre-treatment did not eliminate metastases
altogether, it should be noted that in our experimental protocol,
supra-‘physiological’ numbers of highly malignant tumor cells
were being introduced into the circulation. It is therefore plausible
that the metastasis-inhibiting effect of BAPN might prove even
more complete in ‘real life’ scenarios where circulating tumor cell
concentrations are thought to be exceedingly low. Although it is
conceivable that BAPN can target other cellular molecules in
addition to LOX, our findings suggest that LOX inhibition was
responsible for the diminished tissue colonization by the
circulating MDA-MB-231 cells.
Newly extravasated tumor cells are thought to remain quiescent
during the first few days after intra-cardiac injection, only forming
small metastatic foci (with less than 10 cells per focus) by the end of
the first week [33,41]. Observations using intra-vital microscopy
have revealed that most of tumor cells introduced into the blood
stream by intracardiac or tail vein injection adhere to the blood
vessel endothelium during the first 5 min to 1 hr post-injection,
extend their processes between the gaps in the endothelium and
undergo trans-endothelium migration 30 min to 3 hrs later, and
then complete their extravasation by 3–4 hrs post-injection
Figure 4. Correlation between tumor bioluminescence and osteolytic lesions. Representative bioluminescence images (A, B, E, F) and
corresponding 3D mCT reconstructions for some of the most common skeletal sites of bone metastases in NIH-III mice following intracardiac injection
of MDA-MB-231-Luc2 cells: jaw (C), scapula (D), knee (G), ribs (H), pubis/ischium (I) parietal bone of the skull (J), and thoracic spine (K). Scale bar on
the right of images represents intensity of bioluminescence in photons/s/cm
2.
doi:10.1371/journal.pone.0005620.g004
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endothelial matrix, and begin to remodel the surrounding tissue
stroma allowing the subsequent colonization and growth of
metastases [44]. Thus, the reduction of whole body tumor burden
in mice pre-treated (day 21) with BAPN was likely a result of
LOX inhibition during the initial steps of tumor cell interaction
with the blood vessel epithelium; while the effect of BAPN in the
‘day 0’ group may have been due LOX inhibition during the later
stages of extravasation and initial tissue colonization.
In blood vessels LOX is expressed both the endothelium and the
vascular smooth muscle cells [14,45,46,47]; LOX expression is
also upregulated in invasive breast cancer cells [22,23]. During
catalytic deamination, LOX generates hydrogen peroxide, a
species that can act as a chemoattractant for vascular smooth
muscle cells [18] and breast cancer cells [20], and that also
activates FAK and Src [20]; in this way, LOX may be able to
indirectly modulate cell adhesion and motility [17,48]. In addition,
in vitro studies have shown that exposure of endothelial cells to
hydrogen peroxide increases the permeability of this barrier
[49,50,51,52,53]. Perhaps consistent with their ability to regulate
blood vessel permeability, inhibition of FAK or Src signal
transduction reduces tumor cell extravasation [43,54]. Thus, a
number of lines of research suggest a role for the FAK and Src
kinases in regulation of vascular permeability during tumor cell
extravasation, with LOX playing a regulatory role in this process.
Our results suggest that LOX inhibition, perhaps by diminishing
FAK activity [20], is able to suppress tumor cell-endothelial
adhesion and/or extravasation. This might be of potential
therapeutic relevance at times when elevated numbers of tumor
cells are present in the circulation, such as immediately after breast
cancer surgery [55,56].
LOX up-regulation has been correlated with a worse prognosis
breast cancer, thus, in addition to its induction during hypoxia
[16], it has been proposed that LOX might be required for the
growth of already established metastases [57]. Our results,
however, show that once metastases have developed, BAPN
administration had no appreciable impact on tumor growth. This
was consistent with the findings of Erler and colleagues who
Figure 5. Development of MDA-MB-231-Luc2 metastases in the knees of mice receiving BAPN as compared to controls.
Representative ventral bioluminescence images of control and BAPN-treated mice are shown for the days 7 and 21 following injection of cells (A)
with circles over the knees illustrating the placement of the regions of interest (ROI). (B) H&E stained sections showing the growth plate (GP), cortical
bone (CB), trabecular bone (TB), bone marrow (BM), and tumor area (T) of representative right femurs; the scale bar is 50 mm. (C) Knee
bioluminescence increases over time; at day 7 (D), and day 21 (E) after cell injection. Signals were quantified from dorsal and ventral knee ROI and
graphed as mean photons/s6SEM (n=10 for each of ‘no BAPN’ and for ‘BAPN d 7’ groups, and n=5 for ‘BAPN d 21’ and for ‘BAPN d 0’ groups).
Asterisks indicate statistical significance (
* P,0.05;
** P,0.01;
*** P,0.001).
doi:10.1371/journal.pone.0005620.g005
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formation of metastases at distant sites, it had no effect on the
growth rate of MDA-MB-231 tumors at the orthotopic implan-
tation site [16].
An advantage of the intracardiac route to study metastatic
behavior of tumor cells lies in the high frequency with which
metastases in multiple skeletal and soft tissue sites are obtained in
this model [58]. MDA-MB-231-Luc2 cells formed metastases with
frequencies and tissue- and site-specific patterns similar to those
observed in individuals with metastatic breast cancer [36,37]. Since
catalyticallyactiveLOX,whoselevels couldplausiblydiffer between
vascular beds, may be able to act as a chemoattractant and a
modulator of adhesion and the invasiveness of tumor cells [17,20],
we investigated whether BAPN administration would alter the
anatomical pattern of metastases. Although BAPN pre-treatment
significantly reduced the total number of tumor deposits, it failed to
significantly alter the anatomical pattern of metastases.
Evaluation of the effect of BAPN on the development of skeletal
metastases was of special interest as bones were the most common
site of metastasis observed in our mice after the intra-cardiac
injections of MDA-MB-231-Luc2 cells, and they also represent the
most common site of metastasis in breast cancer [37,38]. Our
findings demonstrated that BAPN was able to reduce the
development of bone metastases. Thus, in mice where the BAPN
treatment was initiated on day 21, tumor burden in knees was
reduced about 9–fold at day 7 post-injection as compared to
controls. Our observations at earlier time points (data not shown),
that were in agreement with previous reports [41] (and our own
unpublished data), demonstrating that breast cancer cells tend to
colonize mouse bones in the region of the primary spongiosa
immediately beneath the epiphyseal growth plate. Perhaps LOX
activity [18,20,59], in combination with other factors released by
osteoblasts, hypertrophic chondrocytes, and/or stromal cells
promotes tumor cell chemo-attraction, motility, proliferation,
and survival at these skeletal sites.
In summary, the LOX inhibitor, BAPN, was able to
significantly decrease the frequency of metastases in animals were
challenged by the introduction of large number of breast cancer
cells directly into the arterial circulation. Our results suggest that
LOX plays an important role in extravasation and/or tissue
colonization by tumor cells, lending support to the idea that LOX
inhibition might be useful in metastasis prevention.
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